Lymphatica Medtech, a Lausanne, Switzerland-based clinical-stage company specialized in innovative treatments for lymphedema, raised €17.9m in Series B funding.
The round was co-led by Panakès Partners, TechWald Next S.p.A., and CDP Venture Capital’s Digital Transition Fund, with participation from OCCIDENT, Zürcher Kantonalbank, and Club Degli Investitori. Existing investors, including High-Tech Gründerfonds (HTGF), also participated in this round.
The company intends to use the funds to accelerate the clinical development and validation of LymphoDrain, an implantable device designed to treat lymphedema, a chronic vascular condition that currently has no cure and affects millions worldwide.
Founded in July 2017, and led by CEO Marco Pisano, and COO Valentina Triacca, Lymphatica Medtech is a medical device company has developed LymphoDrain, a breakthrough implantable device designed to treat lymphedema. LymphoDrain is easy to implant subcutaneously through a minimally invasive technique, which locally and actively replaces the lymphatic vessels draining function.
The company is a spin-off of the Swiss Federal Institute of Technology, Lausanne (EPFL) and of the Lausanne University Hospital (CHUV).
To support its growth, Lymphatica has also opened a subsidiary in Italy to expand its R&D efforts and manage manufacturing and clinical operations.
Lymphatica is further strengthened by the appointment of Dan Rose as the new Chairman of the Board; Rose brings extensive leadership experience from LimFlow (acquired by Inari Medical), Direct Flow Medical, Sequana Medical, and Medtronic. Additionally, Alessio Beverina, Managing Partner at Panakès, and Lukas Guenther, Chief Investment Officer at TechWald Next, have joined the Board of Directors, alongside existing independent board member Nanci Govinder.
FinSMEs
09/10/2024